Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001437749-25-003178·Gem Pharmaceuticals LLC
Schedule 13D ownership disclosure
Monopar Therapeutics Inc
Common Stock, $0.001 par value · CUSIP: 61023L207
Event date: 2024-12-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Monopar TherapeuticsReported CIK 0001645469
Shares: 611,079.00 · Class: 11.6%
- Hendricks DianeReported CIK 0001727478
Shares: 704,829.00 · Class: 13.4%
- Leo KarlReported CIK 0001727480
Shares: 642,391.00 · Class: 13.4%
- Pharma Investments LLCReported CIK 0001727496
Shares: 611,079.00 · Class: 11.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001437749-25-003178
- Form type
- SCHEDULE 13D/A
- Filer
- Gem Pharmaceuticals LLC
- CIK
- CIK 1727356
- Filed
- Feb 07, 2025
- Reporting period
- Dec 09, 2024
- Description
- Schedule 13D beneficial ownership